Expression of miRNA in 5-FU resistant esophageal cancer

被引:9
|
作者
Mahawongkajit, Prasit [1 ]
Tomtitchong, Prakitpunthu [1 ]
机构
[1] Thammasat Univ, Fac Med, Dept Surg, Rangsit Campus,99-209 Moo 18,Paholyothin Rd, Amphur Klongluang 12120, Pathumthani, Thailand
关键词
microRNA; 5-FU resistant; esophageal squamous carcinoma cell; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR; NEOADJUVANT; MICRORNAS; SURVIVAL; SURGERY; ADENOCARCINOMA; POLYMORPHISM; OXALIPLATIN; CISPLATIN;
D O I
10.3892/mco.2020.2070
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fluoropyrimidine plus platinum (FP) are chemotherapeutic drugs that are most frequently used to treat esophageal squamous cell carcinoma (ESCC). However, drug resistance often occurs, and the mechanisms of resistance to 5-FU is yet to be determined. The role of micro (mi)RNAs has been well established in a variety of human cancers. The aim of the present study was to investigate the expression profile of ESCC, revealing the differential expression between ESCC and 5-FU resistant ESCC. The establishment of a 5-FU resistant (5-FUR) cell lines model provides a way of analyzing the expression of miRNAs in drug resistance. The miRNA expression indicated 50 miRNAs that were upregulated in TE10-5-FUR compared with TE10, while 119 miRNAs were downregulated. The TE11-5-FUR demonstrated 140 miRNAs were upregulated compared with TE11, which exhibited 12 downregulated miRNAs. Both cell lines share the 2 candidate upregulated miRNAs (miR-146a and miR-483-5p) and 5 downregulated miRNAs (miR-34a, miR-141, miR-200b, miR-200c and miR-205). Further studies are required to analyze and evaluate the function of the miRNAs.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [11] Chemoradiotherapy using low-dose protracted infusion of 5-FU alone is as effective as 5-FU combined with cisplatin for Advanced esophageal cancer
    Sasamoto, R.
    Tsuchida, E.
    Abe, E.
    Fukuda, T.
    Kawaguchi, G.
    Sasai, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S290 - S290
  • [12] Efficacy of adjuvant chemotherapy with 5-FU/leucovorin and 5-FU/levamisole colon cancer
    Porschen, R
    Bermann, A
    Löffler, T
    Haack, G
    Rettig, K
    Anger, Y
    Strohmeyer, G
    [J]. GASTROENTEROLOGY, 1998, 114 (04) : A664 - A664
  • [13] Radiotherapy and concurrent chemotherapy (low dose 5-FU and CDDP) for esophageal cancer
    Shigematsu, N.
    Fukada, J.
    Kitagawa, Y.
    Kutsuki, S.
    Kubo, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S311 - S311
  • [14] 5-FU induced encephalopathy during 5-FU containing regimen for esophageal squamous cell carcinoma.
    Kato, Ken
    Akiyoshi, Kohei
    Hokamura, Nobukazu
    Igaki, Hiroyasu
    Tachimori, Yuji
    Honma, Yoshitaka
    Iwasa, Satoru
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [15] Colorectal cancer - Is there an alternative to 5-FU?
    Bleiberg, H
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 536 - 541
  • [16] PHASE-II STUDY OF CISPLATIN, 5-FU, AND ALLOPURINOL IN ADVANCED ESOPHAGEAL CANCER
    DEBESI, P
    SILENI, VC
    SALVAGNO, L
    TREMOLADA, C
    CARTEI, G
    FOSSER, V
    PACCAGNELLA, A
    PERACCHIA, A
    FIORENTINO, M
    [J]. CANCER TREATMENT REPORTS, 1986, 70 (07): : 909 - 910
  • [17] A multidisciplinary treatment approach using docetaxel, nedaplatin, and 5-FU for advanced esophageal cancer
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Kikuchi, Shohei
    Sato, Yasushi
    Takada, Koichi
    Miyanishi, Koji
    Kato, Junji
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [18] Development of 5-FU modified tumor suppressor miRNAs as a platform for miRNA based cancer therapeutics
    Fesler, Andrew
    Guo, Shixiang
    Ye, Zachary
    Godwin, Matthew
    Wang, Hyaizha
    Ju, Jingfang
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [19] Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens
    Bajetta, E
    DiBartolomeo, M
    Somma, L
    DelVecchio, M
    Artale, S
    Zunino, F
    Bignami, P
    Magnani, E
    Buzzoni, R
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 687 - 690